Beyond Weight Loss: GLP-1 Drugs Enter the Eating Disorder Conversation

By Irene Yeh 

Originally developed to treat type 2 diabetes and later for obesity management, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are rapidly expanding into other areas of treatment. Researchers are asking whether these medications could play a role in treating eating disorders—a question that brings forth optimism and caution.  

Two studies illustrate the potential of treatment and GLP-1 RA abuse. The first study, conducted by researchers from University College London and published in eClinical Medicine (DOI: 10.1016/j.eclinm.2026.104007), explores the possibility of GLP-1 RAs being used to help reduce binge eating symptoms among overweight or obese patients. The second study (JAMA Psychiatry, DOI: 10.1001/jamapsychiatry.2026.1716) from University of Louisville found that the medications are being used—and sometimes misused—by individuals with eating disorders despite lacking approval for those conditions. Together, the findings highlight the potential of these therapies while urging careful patient selection and multidisciplinary care. 

Encouraging Results for Binge Eating Disorder and Symptoms 

Binge eating is defined as consuming large quantities of food accompanied by a sense of loss of control. Because of the appetite suppression qualities of GLP-1 RAs, researchers from the University College London conducted a systemic review and meta-analysis that examined 25 randomized controlled trials involving 8,069 participants from 12 countries across four continents. Analysis found that GLP-1 RAs reduced binge eating symptoms, including emotional eating and loss of control eating, among individuals who were overweight or obese. Binge eating-related symptoms, when compared to controls, showed consistent reductions with small-to-moderate reductions in binge eating severity (-0.23), disinhibited eating (-0.54), and loss of control eating (-18.38). When binge-eating related outcomes were combined, GLP-1 RAs remained associated with moderate overall reduction in symptom severity (-0.5). 

The review also found an increase in dietary restraint among participants receiving GLP-1 therapy. However, whether that change reflects healthier self-regulation or a more problematic pattern of restrictive eating remains uncertain. 

“From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating,” said Izzy Emptage, Ph.D. candidate at UCL Psychiatry and first author of the study, in a press release.  

The researchers cautioned that their study contained limitations. The relatively small trial sample size contained differences in outcome measures, follow-up periods, and participant and intervention characteristics, which limited the team’s ability to determine whether certain patient populations or dosing strategies produce better outcomes. They also noted that all of the studies focused on individuals with overweight or obesity, leaving unanswered questions about the effects of GLP-1 RAs in people with binge eating disorder who are not overweight or obese. Furthermore, some studies used had effect estimates that were calculated using data from results that were incomplete or inconsistent, resulting in potential further inaccuracy and uncertainty. 

Growing Concerns Surrounding Misuse 

While researchers continue investigating GLP-1 RAs as a potential therapeutic tool, on the other end of the spectrum is the concern that these medications are being misused for anorexia nervosa, bulimia, and other eating disorders centered around weight loss.  

In the cross-sectional survey published in JAMA Psychiatry, researchers examined GLP-1 medication use among individuals with eating disorders and collected information on compounded GLP-1 products and misuse, such as taking higher doses than prescribed, changing doses without medical guidance, using the mediation longer than directed, tampering with injection devices, or sharing medications with others. Among the 436 participants, 32.1% reported lifetime GLP-1 use, while 22% reported current use. Lifetime misuse accounted for 10.1% of participants, and 9.9% reported using compounded GLP-1 products. 

Lifetime GLP-1 RAs use was more common among people with eating disorders than the 15% reported in the general adult population. Because GLP-1 RAs are not approved to treat eating disorders, the findings suggest that some patients may be using the medications for unhealthy weight loss. The research team also called for increased monitoring of GLP-1 RAs as they become more widely available, especially in the commercial and compounded product front.  

The authors of the study acknowledged that the cross-sectional design, nonrandom sampling, and self-reported data could have skewed the results. Further research is needed, they said, to examine differences across eating disorder subtypes and demographic groups. There also needs to be a close examination of key correlations, such as patterns of misuse, where the drugs are sourced, reasons for use, off-label use, and marketing exposure. 

A Tool, Not a Cure 

Though both studies approached the topic from different angles, they share an underlying conclusion: GLP-1 RAs should not be viewed as a standalone solution for eating disorders. 

The University College London research team emphasized the need for longer-term studies to determine whether improvements persist after treatment ends and whether combining GLP-1 therapy with psychological interventions enhances or interferes with recovery. They noted that reducing food cravings could potentially lessen opportunities for patients to practice coping strategies taught through cognitive behavioral therapy, raising important questions about how medications and psychotherapy should be integrated. 

The emerging evidence shows that screening patients for disordered eating behaviors before initiating GLP-1 RA therapy and monitoring both psychological and metabolic outcomes throughout treatment are critical. While the medications may eventually become an important option for carefully selected patients with binge eating disorder, clinicians must also remain alert to unintended consequences, including misuse among vulnerable populations. 

This perspective of GLP-1 RAs as a tool and not a cure seems to be growing across different fields, as well. At the Integrative Health Symposium earlier this year in New York City, Monique Class, co-founder of The Center for Functional Medicine and The Institute for Functional Nursing, held a presentation that discussed microdosing GLP-1 RAs to give patients a moment of hesitation and the opportunity to choose not to eat or drink something. She also mentioned that GLP-1 RAs have an anti-inflammatory effect, and even just one milligram can reduce join pain, decrease brain inflammation, and improve depression. Though the medications have proven effective, Class warned that GLP-1 RAs are not a cure-all and that lifestyle interventions are the key to ensuring patients maintain their health. 

As research continues to evolve, the role of GLP-1 RAs in eating disorder care appears neither straightforward nor universally applicable. Instead, the medications may ultimately find their place as one component of a broader, individualized treatment strategy that addresses both the biological and psychological needs of these complex disorders.